Computer method IMPACT-F replaces unreliable animal tests

Experiments in animals are used to estimate drug-uptake in humans. If drug-uptake in animals is too low, drug candidates are excluded from further development.

But large differences exist on drug-uptake between animals and humans. This also applies to very successful commercial drugs, called blockbuster drugs, with annual sales of more than one billion US Dollar.

Drug-uptake studies in animals are misleading: Aripiprazole and Esomeprazole, the most sold drugs of 2013, have low oral bioavailability in animals, but drug-uptake in humans is high.

The new expert system IMPACT-F replaces animal trials on drug-uptake.

Pharmaceutical companies have applied the expert system to evaluate human drug-uptake in various therapeutic areas such as diabetes, inflammation, antivirals, autoimmune diseases and cancer.

The expert system evaluates drug-uptake in humans significantly more reliably than animal trials. This further increases the prospects of human clinical trials, because the optimum oral dose for first-in-human clinical trials can be determined much more accurately.

Efficacy issues are identified as the main reason why clinical trials fail.

About PharmaInformatic:
The biotech company PharmaInformatic was founded in 2004 and provides ADME knowledge bases and predictive tools (expert systems) to improve drug discovery and development. The company is based in Germany.
www.pharmainformatic.com


Further detailed information:
http://www.pharmainformatic.com/html/partnerships.html

http://www.pharmainformatic.com/html/blockbuster_drugs.html

URL: http://www.pharmainformatic.com

Contact Person: Dr. Wolfgang Boomgaarden (presse@pharmainformatic.com)